We are thrilled to announce a major milestone in advancing clinical research in Malaysia! Dr. David Lee Dai Wee and his dedicated study team at UMMC have successfully randomized the first patient in Malaysia for the eVOLVE-HNSCC study—a Phase III, global clinical trial sponsored by AstraZeneca. This trial aims to evaluate the effectiveness of Volrustomig (MEDI5752) as sequential therapy versus observation in participants with unresected, locally advanced Head and Neck Squamous Cell Carcinoma (HNSCC) who have not progressed following definitive concurrent chemoradiotherapy.
A Remarkable Achievement
This milestone is even more remarkable, considering it was achieved just one month after site activation. Such rapid progress is a testament to the relentless efforts and collaboration of the entire team. We extend our heartfelt congratulations to Dr. David and his study team for their exceptional dedication, hard work, and commitment to improving treatment options for patients with HNSCC.
A special shout-out goes to Study Coordinator Ms. Toh Yok Yong for her outstanding commitment and support throughout the screening and recruitment process. Her meticulous attention to detail and seamless coordination have played a vital role in this success.
We look forward to supporting the team as we collectively work to improve outcomes for patients with HNSCC.
Stay tuned for more updates on the progress of the eVOLVE-HNSCC study and other clinical research milestones at UMMC.
#ClinicalTrials #HeadAndNeckCancer #CICUMMC #EVOLVEHNSCC #UMMC #ResearchMilestone #InnovationInHealthcare